Please ensure Javascript is enabled for purposes of website accessibility

Will Co-Diagnostics Stock Go to $30?

By Cory Renauer – May 20, 2020 at 2:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For the molecular diagnostics company to earn such a big boost in its valuation, sales of its COVID-19 test will need to grow at an ambitious rate.

Jason McCarthy, an analyst at Maxim Group, has raised the investment bank's rating on Co-Diagnostics (CODX 5.23%). Increasing sales of Co-Diagnostics' test for COVID-19 led McCarthy to upgrade the stock to a buy and give it a $30 price target.

A 63% gain ahead?

Despite McCarthy's ambitious new price target and rating upgrade, shares of Co-Diagnostics fell about 2.5% during the first half of Wednesday's trading session. At the stock's recent price of $18.27, Maxim's new target suggests a 63% gain once the rest of the market sees the company's future in the same light as McCarthy.

Pipette dripping a dollar sign.

Image source: Getty Images.

As Co-Diagnostics revealed in the earnings report it delivered last week, sales of the Logix Smart CODIV-19 test helped lift its total revenue to $1.5 million during the first quarter, but analysts following the company expect enormous gains from there when the company reports on Q2. Co-Diagnostics has boosted production capacity at its main facility in Salt Lake City and at a plant in India as part of a joint venture to meet soaring demand. With distribution across 15 U.S. states, plus dozens of countries around the world eager to contain their own COVID-19 outbreaks, sales of the company's molecular diagnostic could pass $80 million in 2020.

Play it safe

At recent prices, Co-Diagnostics stock is trading at about 6.2 times 2020 sales expectations, which isn't a bad price to pay if you can assume the company will continue raising sales at a moderate pace throughout the COVID-19 pandemic and beyond.

Before jumping in head first, though, it's important to realize that reaching Maxim's price target will require some rapid scaling of operations that this relatively young company might not be ready for. If the market sees doesn't see sales rising fast enough when the company reports again in a few months, this stock's price could quickly come crashing down.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$3.02 (5.23%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.